You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Though Teva (TEVA) faces several challenges, with encouraging progress on restructuring activities and stabilization in the generics business, it may return to growth in 2020 or 2021.
FDA approves line extensions for Bristol-Myers (BMY), Roche (RHHBY) and AstraZeneca (AZN)/Merck's (MRK) drugs. J&J stops sales of talc-based baby powders in the United States and Canada.
Biotech companies and drugmakers are speeding up development of a vaccine for COVID-19. This has seen many big players joining forces to come up with a treatment.
FDA approves AstraZeneca (AZN)/Merck's (MRK) PARP inhibitor Lynparza for HRR gene-mutated metastatic castration-resistant prostate cancer. The approval was based on data from the phase III PROfound study.
The FDA assigns a Breakthrough Therapy status to AstraZeneca's (AZN) Enhertu for treating patients with metastatic NSCLC whose tumors have a HER2 mutation.
Drugmakers and biotech companies are initiating development of drugs, vaccines and therapies for COVID-19 and substantial progress has been made over the past month.
Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), Johnson & Johnson (JNJ) and Fidelity National Information Services, Inc. (FIS).
Pfizer's (PFE) new phase Ib data on its investigational gene therapy, PF-06939926 in ambulatory boys with DMD support advancement to a pivotal phase III study.
FDA approves Lilly's (LLY) selpercatinib for RET-altered lung and thyroid cancers and AstraZeneca (AZN)/Merck's (MRK) Lynparza for new ovarian cancer use.
pharmaceuticals: Archive
Roche Acquires Stratos Genomics, Presents Data on NMOSD Drug
by Zacks Equity Research
Roche (RHHBY) acquires Stratos Genomics to advance the development of its nanopore sequencer as well as releases positive data on its NMOSD Drug.
RHHBY MRK AMGN AGN
pharmaceuticals
Can Teva (TEVA) Return to Growth in This Year or Next?
by Zacks Equity Research
Though Teva (TEVA) faces several challenges, with encouraging progress on restructuring activities and stabilization in the generics business, it may return to growth in 2020 or 2021.
TEVA GILD MRK LLY
pharmaceuticals
Pharma Stock Roundup: FDA Ok's Cancer Drugs for New Use, JNJ Stops US Baby Powder Sales
by Kinjel Shah
FDA approves line extensions for Bristol-Myers (BMY), Roche (RHHBY) and AstraZeneca (AZN)/Merck's (MRK) drugs. J&J stops sales of talc-based baby powders in the United States and Canada.
JNJ AZN RHHBY PFE MRK GSK BMY
pharmaceuticals
Coronavirus Vaccine Race Pushes Up Pharma Giants' Production
by Ritujay Ghosh
Biotech companies and drugmakers are speeding up development of a vaccine for COVID-19. This has seen many big players joining forces to come up with a treatment.
SNY PFE MRNA BNTX
biotechs medical pharmaceuticals
Dr. Reddy's (RDY) Q4 Earnings Increase Y/Y, Revenues Beat
by Zacks Equity Research
Dr. Reddy's (RDY) fourth-quarter earnings and sales increase year over year.
RDY VRTX ABBV
earnings pharmaceuticals
AstraZeneca/Merck's Lynparza Get FDA Nod for Prostate Cancer
by Zacks Equity Research
FDA approves AstraZeneca (AZN)/Merck's (MRK) PARP inhibitor Lynparza for HRR gene-mutated metastatic castration-resistant prostate cancer. The approval was based on data from the phase III PROfound study.
AZN PFE MRK CLVS
pharmaceuticals
Will Milestone Pharmaceuticals Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor of Milestone Pharmaceuticals
MIST
pharmaceuticals
These 4 High Earnings Yield Stocks are Hot Investment Picks
by Zacks Equity Research
Earnings yield has an edge over P/E ratio as it can be used to compare a stock with not just other stocks but also with fixed income securities.
GILD CEMI BMY BTG
gold medical pharmaceuticals precious-metals
J&J to Stop Sale of Talc-Based Baby Powder in North America
by Zacks Equity Research
J&J (JNJ) faces thousands of lawsuits, which claim that its talc-based products, primarily its baby powders, cause cancer.
JNJ PFE LLY ABBV
pharmaceuticals
AstraZeneca's Enhertu Gets Breakthrough Therapy Tag for NSCLC
by Zacks Equity Research
The FDA assigns a Breakthrough Therapy status to AstraZeneca's (AZN) Enhertu for treating patients with metastatic NSCLC whose tumors have a HER2 mutation.
AZN LLY GSK INVA
pharmaceuticals
Glaxo's Long-Acting HIV Injection Effective Than Daily Pills
by Zacks Equity Research
Glaxo's (GSK) long-acting injectable formulation of cabotegravir dosed every two months shows higher efficacy than daily oral pills.
JNJ PFE GILD GSK
pharmaceuticals
Novartis Gets EC Approval for Gene Therapy Zolgensma in SMA
by Zacks Equity Research
Novartis' (NVS) gene therapy, Zolgensma, obtains EC approval for spinal muscular atrophy.
BIIB RHHBY NVS BAYRY
biotechs pharmaceuticals
Roche's Tecentriq Gets FDA Approval for Metastatic NSCLC
by Zacks Equity Research
Roche (RHHBY) gets FDA approval for the label expansion of Tecentriq into metastatic NSCLC as a first-line monotherapy.
AZN RHHBY MRK BMY
pharmaceuticals
5 Biotech Stocks in Focus as Race for Coronavirus Vaccine Heats Up
by Ritujay Ghosh
Drugmakers and biotech companies are initiating development of drugs, vaccines and therapies for COVID-19 and substantial progress has been made over the past month.
REGN SNY PFE GILD MRNA GSK AMGN CYDY ADPT BNTX
biotechs medical pharmaceuticals
Bull of the Day: Vertex Pharma (VRTX)
by Kevin Cook
While COVID-19 interrupts clinical trials, the champ of cystic fibrosis is about to repeat another year of 37% revenue growth
VRTX CRSP
biotechs genetics genomics medical pharmaceuticals
Top Ranked Momentum Stocks to Buy for May 19th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, May 19th
UNFI SYRS MIST AGFS
consumer-discretionary consumer-staples medical pharmaceuticals
New Strong Buy Stocks For May 19th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
MTSI HCFT FARO AT ABBV
biotechs finance pharmaceuticals
Top Stock Reports for Facebook, JNJ, FIS & Others
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), Johnson & Johnson (JNJ) and Fidelity National Information Services, Inc. (FIS).
JNJ FIS FB CMCSA BMY BABA
business-services consumer-discretionary finance internet pharmaceuticals tech-stocks
Bristol Myers' Opdivo+Yervoy Gets FDA Nod in First-Line NSCLC
by Zacks Equity Research
Bristol-Myers (BMY) Opdivo in combination with Yervoy gets FDA nod for the first-line treatment of NSCLC patients.
AZN RHHBY MRK BMY
biotechs pharmaceuticals
Pfizer Reports Efficacy & Safety Data on DMD Gene Therapy
by Zacks Equity Research
Pfizer's (PFE) new phase Ib data on its investigational gene therapy, PF-06939926 in ambulatory boys with DMD support advancement to a pivotal phase III study.
PFE SRPT PTCT SLDB
pharmaceuticals
Moderna (MRNA) COVID-19 Vaccine Looks Promising
by Mark Vickery
This news comes sooner and more positive than analysts had been expecting, and shares are up 35% in early trading this Monday.
MRNA SPY QQQ DIA
pharmaceuticals
Q1 Scorecard and Research Reports for NVIDIA, Coca-Cola, PetroChina & Others
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA (NVDA), Coca-Cola (KO) and PetroChina (PTR).
ZM QCOM PTR NVDA KO CVS
communications consumer-discretionary internet oil-energy pharmaceuticals retail semiconductor
Merck's (MRK) Keytruda Successful in Several Cancer Studies
by Zacks Equity Research
Merck (MRK) announces positive data from several cancer studies evaluating Keytruda across multiple indications.
RHHBY MRK BMY SGEN
pharmaceuticals
Pharma Stock Roundup: FDA Updates for LLY, AZN, MRK, BMY and SNY
by Kinjel Shah
FDA approves Lilly's (LLY) selpercatinib for RET-altered lung and thyroid cancers and AstraZeneca (AZN)/Merck's (MRK) Lynparza for new ovarian cancer use.
SNY AZN MRK LLY BMY ABBV
pharmaceuticals
Roche Posts Positive Phase II Results on Immunotherapy Combo
by Zacks Equity Research
Roche's (RHHBY) mid-stage study on immunotherapy, tiragolumab, combined with PD-L1 checkpoint inhibitor, Tecentriq, meets co-primary endpoints.
AZN RHHBY MRK BMY
pharmaceuticals